DK1816204T3 - Rekombinant adenovirus af Ad26-serotypen - Google Patents

Rekombinant adenovirus af Ad26-serotypen

Info

Publication number: DK1816204T3
Authority: DK; Denmark
Prior art keywords: serotypes; adenovirus; tropism; proteins; natural
Prior art date: 1999-05-17

Application number

DK07106044.6T

Other languages

English (en)

Inventor

Ronald Vogels

Abraham Bout

Menzo Jans Emko Havenga

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-17

Filing date

2000-05-16

Publication date

2011-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1816204(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-16 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2011-01-24 Application granted granted Critical

2011-01-24 Publication of DK1816204T3 publication Critical patent/DK1816204T3/da

Links

241000701161 unidentified adenovirus Species 0.000 title abstract 5
108090000565 Capsid Proteins Proteins 0.000 abstract 3
102100023321 Ceruloplasmin Human genes 0.000 abstract 3
230000010415 tropism Effects 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
101710145505 Fiber protein Proteins 0.000 abstract 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK07106044.6T 1999-05-17 2000-05-16 Rekombinant adenovirus af Ad26-serotypen DK1816204T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99201545		1999-05-17
EP04077434A EP1550722B1 (en)	1999-05-17	2000-05-16	Recombinant human adenovirus serotype 35

Publications (1)

Publication Number	Publication Date
DK1816204T3 true DK1816204T3 (da)	2011-01-24

Family

ID=8240209

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
DK07106036.2T DK1818408T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af serotypen Ad11
DK07106054.5T DK1816205T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus på grundlag af serotypen Ad48
DK04077434T DK1550722T3 (da)	1999-05-17	2000-05-16	Rekombinant human adenovirus serotype 35
DK07106044.6T DK1816204T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af Ad26-serotypen
DK05077719T DK1681353T3 (da)	1999-05-17	2000-05-16	Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK00201738.2T DK1054064T4 (da)	1999-05-17	2000-05-16	Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
DK07106036.2T DK1818408T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af serotypen Ad11
DK07106054.5T DK1816205T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus på grundlag af serotypen Ad48
DK04077434T DK1550722T3 (da)	1999-05-17	2000-05-16	Rekombinant human adenovirus serotype 35

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK05077719T DK1681353T3 (da)	1999-05-17	2000-05-16	Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK00201738.2T DK1054064T4 (da)	1999-05-17	2000-05-16	Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35

Country Status (14)

Country	Link
EP (6)	EP1054064B2 (da)
JP (2)	JP4843145B2 (da)
KR (1)	KR100741247B1 (da)
AT (6)	ATE519855T1 (da)
AU (1)	AU777041B2 (da)
CA (1)	CA2372655C (da)
CY (4)	CY1106762T1 (da)
DE (4)	DE60014489T3 (da)
DK (6)	DK1818408T3 (da)
ES (5)	ES2372824T3 (da)
IL (3)	IL146479A0 (da)
NZ (1)	NZ515582A (da)
PT (5)	PT1816204E (da)
WO (1)	WO2000070071A1 (da)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
SI0833934T2 (sl)	1995-06-15	2013-04-30	Crucell Holland B.V.	Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US20030017138A1 (en)	1998-07-08	2003-01-23	Menzo Havenga	Chimeric adenoviruses
US6929946B1 (en)	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en)	1999-03-04	2005-03-22	Crucell Holland B.V.	Means and methods for fibroblast-like or macrophage-like cell transduction
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
US7094398B1 (en)	1999-06-01	2006-08-22	University Of Washington	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en)	1999-11-23	2003-05-06	Stefan Kochanek	Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) *	2000-09-25	2002-03-27	Galapagos Genomics B.V.	Gene delivery vectors provided with a tissue tropism for T-lymphocytes
JP2003534805A (ja)	2000-05-31	2003-11-25	ユニバーシティオブサスカチュワン	変化した親和性を有する改変ウシアデノウイルス
CA2421864A1 (en) *	2000-09-20	2002-03-28	Crucell Holland B.V.	Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de)	2000-09-26	2009-05-28	Crucell Holland Bv	Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2002029073A2 (en) *	2000-10-06	2002-04-11	Crucell Holland B.V.	Gene delivery vectors for stem cells
EP1195440A1 (en) *	2000-10-06	2002-04-10	Introgene B.V.	Gene delivery vectors for stem cells
ATE449859T1 (de) *	2001-01-04	2009-12-15	Goeran Wadell	Virusvektor zur gentherapie
WO2002068627A2 (en)	2001-02-23	2002-09-06	Novartis Ag	Vector constucts
WO2003062400A2 (en) *	2002-01-24	2003-07-31	The Scripps Research Institute	Fiber shaft modifications for efficient targeting
DK1497440T3 (da)	2002-04-25	2008-12-01	Crucell Holland Bv	Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
KR101021387B1 (ko)	2002-04-25	2011-03-14	크루셀 홀란드 비.브이.	아데노바이러스 벡터를 생산하기 위한 수단 및 방법
JP4237449B2 (ja) *	2002-06-05	2009-03-11	国立医薬品食品衛生研究所長	アデノウィルスベクター
EP1553983A2 (en)	2002-10-23	2005-07-20	Crucell Holland B.V.	New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en)	2003-10-23	2008-06-26	Crucell Holland B.V.	Settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en)	2002-12-17	2004-07-01	Crucell Holland B.V.	Recombinant viral-based malaria vaccines
AU2004260044B2 (en) *	2003-07-18	2009-04-23	Onyx Pharmaceuticals, Inc.	Subgroup B adenoviral vectors for treating disease
NZ548495A (en)	2004-02-23	2009-05-31	Crucell Holland Bv	Virus purification methods
AU2005243730B2 (en) *	2004-04-12	2010-05-27	Genvec, Inc.	Method of using adenoviral vectors to induce an immune response
US7510868B2 (en)	2004-05-26	2009-03-31	Paul Harden	Chimeric adenoviruses for use in cancer treatment
BRPI0516048A (pt)	2004-10-13	2008-08-19	Crucell Holland B V E Beth Isr	batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
SG159555A1 (en)	2004-11-16	2010-03-30	Crucell Holland Bv	Multivalent vaccines comprising recombinant viral vectors
DK1869171T4 (da)	2005-04-11	2016-01-18	Crucell Holland Bv	Virusrensning under anvendelse af ultrafiltrering
EP1907536B1 (en)	2005-07-22	2010-04-07	Crucell Holland B.V.	Cell line for producing coronaviruses
US20100143302A1 (en) *	2006-03-16	2010-06-10	Crucell Holland B.V.	Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
CN102203242B (zh)	2008-11-03	2013-06-12	克鲁塞尔荷兰公司	产生腺病毒载体的方法
TWI555531B (zh)	2009-08-07	2016-11-01	傳斯堅公司	用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
US20120315696A1 (en) *	2010-02-15	2012-12-13	Alfred Luitjens	METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
MX2012007936A (es) *	2010-02-15	2012-11-22	Crucell Holland Bv	Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
EP2618838A1 (en)	2010-09-20	2013-07-31	Crucell Holland B.V.	Therapeutic vaccination against active tuberculosis
MX354752B (es)	2010-09-27	2018-03-20	Janssen Vaccines & Prevention Bv	Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
CN102260712B (zh) *	2011-05-31	2013-10-02	北京锤特生物科技有限公司	溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja)	2012-03-12	2015-08-26	クルセルホランドベーヴェー	改変末端を有する組換えアデノウイルスのバッチ
US9119813B2 (en)	2012-03-22	2015-09-01	Crucell Holland B.V.	Vaccine against RSV
EA026504B1 (ru)	2012-03-22	2017-04-28	Круселл Холланд Б.В.	Вакцина против rsv
JP6162224B2 (ja)	2012-05-24	2017-07-12	クルセルホランドベーヴェー	血管組織の形質導入のためのアデノウイルスベクター
CN104640564B (zh)	2012-07-10	2020-08-04	特兰斯吉恩股份有限公司	分枝杆菌抗原疫苗
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
EP4631509A3 (en)	2012-11-16	2026-03-04	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and use thereof
AU2014236207B2 (en)	2013-03-14	2019-05-23	Salk Institute For Biological Studies	Oncolytic adenovirus compositions
JP6469081B2 (ja)	2013-04-25	2019-02-13	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	安定化された可溶性融合前ｒｓｖｆポリペプチド
MY171210A (en)	2013-06-17	2019-10-02	Janssen Vaccines & Prevention Bv	Stabilized soluble pre-fusion rsv f polypeptides
AU2014338864C1 (en)	2013-10-25	2020-07-16	Akamis Bio Limited	Oncolytic adenoviruses armed with heterologous genes
EP3092000A1 (en)	2014-01-09	2016-11-16	Transgene SA	Fusion of heterooligomeric mycobacterial antigens
HUE065565T2 (hu)	2014-09-03	2024-06-28	Bavarian Nordic As	Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
MX2017002890A (es)	2014-09-03	2017-11-13	Bavarian Nordic As	Métodos y composiciones para potenciar respuestas inmunitarias.
KR20250081944A (ko)	2014-09-24	2025-06-05	솔크 인스티튜트 포 바이올로지칼 스터디즈	종양 살상 바이러스 및 이의 사용방법
ES2865150T3 (es)	2014-09-26	2021-10-15	Beth Israel Deaconess Medical Ct Inc	Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
HUE040440T2 (hu)	2014-11-04	2019-03-28	Janssen Vaccines & Prevention Bv	Terápiás HPV16-oltóanyagok
WO2016166088A1 (en)	2015-04-14	2016-10-20	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
PE20180241A1 (es)	2015-04-30	2018-01-31	Psioxus Therapeutics Ltd	Adenovirus oncolitico que codifica una proteina b7
CN107847581B (zh)	2015-07-07	2022-03-22	扬森疫苗与预防公司	稳定化的可溶性融合前rsv f多肽
ES2839880T3 (es)	2015-07-07	2021-07-06	Janssen Vaccines & Prevention Bv	Vacuna contra el VRS
KR20180042295A (ko)	2015-08-20	2018-04-25	얀센 백신스 앤드 프리벤션 비.브이.	치료용 hpv18 백신
PT3390430T (pt)	2015-12-15	2019-11-20	Janssen Vaccines & Prevention Bv	Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
EA201891022A1 (ru)	2015-12-17	2019-01-31	Псайоксус Терапьютикс Лимитед	Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
EP4155411A1 (en)	2016-02-23	2023-03-29	Salk Institute for Biological Studies	Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	High throughput assay for measuring adenovirus replication kinetics
PH12022552125A1 (en)	2016-04-05	2023-04-12	Janssen Vaccines & Prevention Bv	Stabilized soluble pre-fusion rsv f proteins
KR102500970B1 (ko)	2016-04-05	2023-02-17	얀센 백신스 앤드 프리벤션 비.브이.	Rsv에 대한 백신
EP3452087A1 (en)	2016-05-02	2019-03-13	Janssen Vaccines & Prevention B.V.	Therapeutic hpv vaccine combinations
IL264119B2 (en)	2016-05-30	2023-04-01	Janssen Vaccines Prevention B V	f proteins of rsv are stabilized before fusion
JP6595132B2 (ja)	2016-06-16	2019-10-23	ヤンセンファッシンズアンドプリベンションベーフェー	Ｈｉｖワクチン製剤
KR102307065B1 (ko)	2016-06-20	2021-09-30	얀센 백신스 앤드 프리벤션 비.브이.	강력하고 균형 잡힌 양방향성 프로모터
US10744196B2 (en)	2016-07-14	2020-08-18	Janssen Vaccines & Prevention B.V.	HPV vaccines
EP3484507A1 (en)	2016-07-15	2019-05-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018011198A1 (en)	2016-07-15	2018-01-18	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against a marburg virus infection
CN119614520A (zh)	2016-08-29	2025-03-14	阿卡米斯生物公司	携带双特异性t细胞衔接器的腺病毒
GB201713765D0 (en)	2017-08-28	2017-10-11	Psioxus Therapeutics Ltd	Modified adenovirus
EP3532082A4 (en)	2016-12-12	2020-08-26	Salk Institute for Biological Studies	SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN110268061B (zh)	2017-02-09	2024-07-16	扬森疫苗与预防公司	用于表达异源基因的有效的短启动子
US11173204B2 (en)	2017-04-06	2021-11-16	Janssen Vaccines & Prevention B.V.	MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
WO2018210871A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
US11229692B2 (en)	2017-05-17	2022-01-25	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against RSV infection
CN110958887B (zh)	2017-06-15	2023-10-31	扬森疫苗与预防公司	编码hiv抗原的痘病毒载体及其使用方法
WO2019053109A1 (en)	2017-09-15	2019-03-21	Janssen Vaccines & Prevention B.V.	METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
BR112020007884A2 (pt)	2017-11-20	2020-11-03	Janssen Pharmaceuticals, Inc.	método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
WO2019118480A1 (en)	2017-12-11	2019-06-20	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and uses thereof
CN111741766A (zh)	2017-12-19	2020-10-02	杨森科学爱尔兰无限公司	用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
MX2020010499A (es)	2018-04-09	2020-10-28	Salk Inst For Biological Studi	Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
US11713469B2 (en)	2018-07-20	2023-08-01	Janssen Vaccines & Prevention B.V.	Recombinant adenoviral vector expressing Zika antigen with improved productivity
JP2022513025A (ja)	2018-11-13	2022-02-07	ヤンセンファッシンズアンドプリベンションベーフェー	安定化された融合前ｒｓｖｆタンパク質
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
US20220273787A1 (en)	2019-05-15	2022-09-01	Janssen Vaccines & Prevention B.V.	Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
US20220193219A1 (en)	2019-05-15	2022-06-23	Janssen Vaccines & Prevention B.V.	Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
KR20220115569A (ko)	2019-11-18	2022-08-17	얀센 바이오테크 인코포레이티드	돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
CN111337042B (zh) *	2020-03-13	2021-11-02	湖北大学	一种车辆路径规划方法及系统
EP4135757A1 (en)	2020-04-13	2023-02-22	Janssen Biotech, Inc.	Psma and steap1 vaccines and their uses
EP4176087A1 (en)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	A method for determining responsiveness to prostate cancer treatment
US12295997B2 (en)	2020-07-06	2025-05-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
WO2022009049A1 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
CN116367854A (zh)	2020-07-08	2023-06-30	杨森科学爱尔兰无限公司	针对hbv的rna复制子疫苗
GB202013940D0 (en)	2020-09-04	2020-10-21	Synpromics Ltd	Regulatory nucleic acid sequences
AU2021358957A1 (en)	2020-10-07	2023-06-08	AskBio Inc.	Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
US12275766B2 (en)	2020-12-23	2025-04-15	Janssen Biotech, Inc.	Neoantigen peptide mimics
WO2023198815A1 (en)	2022-04-14	2023-10-19	Janssen Vaccines & Prevention B.V.	Sequential administration of adenoviruses
WO2025047364A1 (ja) *	2023-08-28	2025-03-06	国立大学法人大阪大学	組換え腫瘍溶解性アデノウイルス

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2725726B1 (fr) *	1994-10-17	1997-01-03	Centre Nat Rech Scient	Vecteurs viraux et utilisation en therapie genique
US5856152A (en) *	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
SI0833934T2 (sl)	1995-06-15	2013-04-30	Crucell Holland B.V.	Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5837511A (en) *	1995-10-02	1998-11-17	Cornell Research Foundation, Inc.	Non-group C adenoviral vectors
US5877011A (en) *	1996-11-20	1999-03-02	Genzyme Corporation	Chimeric adenoviral vectors
US6100086A (en) *	1997-04-14	2000-08-08	Genzyme Corporation	Transgene expression systems
CA2364499C (en) *	1999-03-04	2008-12-23	Introgene B.V.	Means and methods for fibroblast-like or macrophage-like cell transduction
EP2297187A1 (en) *	2008-06-03	2011-03-23	Okairos AG	A vaccine for the prevention and therapy of hcv infections

2000
- 2000-05-16 AT AT07106036T patent/ATE519855T1/de active
- 2000-05-16 AT AT04077434T patent/ATE364707T1/de active
- 2000-05-16 DK DK07106036.2T patent/DK1818408T3/da active
- 2000-05-16 AT AT07106054T patent/ATE519854T1/de active
- 2000-05-16 PT PT07106044T patent/PT1816204E/pt unknown
- 2000-05-16 AT AT05077719T patent/ATE445018T1/de not_active IP Right Cessation
- 2000-05-16 DK DK07106054.5T patent/DK1816205T3/da active
- 2000-05-16 ES ES07106054T patent/ES2372824T3/es not_active Expired - Lifetime
- 2000-05-16 DE DE60014489T patent/DE60014489T3/de not_active Expired - Lifetime
- 2000-05-16 KR KR1020017014631A patent/KR100741247B1/ko not_active Expired - Lifetime
- 2000-05-16 CA CA2372655A patent/CA2372655C/en not_active Expired - Lifetime
- 2000-05-16 JP JP2000618477A patent/JP4843145B2/ja not_active Expired - Lifetime
- 2000-05-16 ES ES00201738T patent/ES2231103T5/es not_active Expired - Lifetime
- 2000-05-16 EP EP00201738A patent/EP1054064B2/en not_active Expired - Lifetime
- 2000-05-16 PT PT00201738T patent/PT1054064E/pt unknown
- 2000-05-16 EP EP07106044A patent/EP1816204B1/en not_active Expired - Lifetime
- 2000-05-16 AT AT07106044T patent/ATE485382T1/de active
- 2000-05-16 DE DE60035229T patent/DE60035229T2/de not_active Expired - Lifetime
- 2000-05-16 AU AU49547/00A patent/AU777041B2/en not_active Expired
- 2000-05-16 IL IL14647988A patent/IL146479A0/xx unknown
- 2000-05-16 DE DE60043126T patent/DE60043126D1/de not_active Expired - Lifetime
- 2000-05-16 DE DE60045138T patent/DE60045138D1/de not_active Expired - Lifetime
- 2000-05-16 PT PT07106036T patent/PT1818408E/pt unknown
- 2000-05-16 ES ES07106036T patent/ES2372823T3/es not_active Expired - Lifetime
- 2000-05-16 ES ES04077434T patent/ES2289426T3/es not_active Expired - Lifetime
- 2000-05-16 EP EP07106054A patent/EP1816205B1/en not_active Expired - Lifetime
- 2000-05-16 DK DK04077434T patent/DK1550722T3/da active
- 2000-05-16 DK DK07106044.6T patent/DK1816204T3/da active
- 2000-05-16 PT PT04077434T patent/PT1550722E/pt unknown
- 2000-05-16 DK DK05077719T patent/DK1681353T3/da active
- 2000-05-16 EP EP05077719A patent/EP1681353B1/en not_active Expired - Lifetime
- 2000-05-16 WO PCT/NL2000/000325 patent/WO2000070071A1/en not_active Ceased
- 2000-05-16 NZ NZ515582A patent/NZ515582A/en not_active IP Right Cessation
- 2000-05-16 AT AT00201738T patent/ATE278792T1/de active
- 2000-05-16 EP EP07106036A patent/EP1818408B1/en not_active Expired - Lifetime
- 2000-05-16 DK DK00201738.2T patent/DK1054064T4/da active
- 2000-05-16 PT PT07106054T patent/PT1816205E/pt unknown
- 2000-05-16 ES ES07106044T patent/ES2354578T3/es not_active Expired - Lifetime
- 2000-05-16 EP EP04077434A patent/EP1550722B1/en not_active Expired - Lifetime
2001
- 2001-11-13 IL IL146479A patent/IL146479A/en not_active IP Right Cessation
2007
- 2007-07-25 CY CY20071100996T patent/CY1106762T1/el unknown
2011
- 2011-01-10 CY CY20111100030T patent/CY1111494T1/el unknown
- 2011-07-14 JP JP2011156125A patent/JP5335037B2/ja not_active Expired - Lifetime
- 2011-08-02 IL IL214413A patent/IL214413A/en not_active IP Right Cessation
- 2011-11-07 CY CY20111101075T patent/CY1112189T1/el unknown
- 2011-11-07 CY CY20111101074T patent/CY1112008T1/el unknown

Also Published As

Publication number	Publication date
EP1681353B1 (en)	2009-10-07
EP1816204B1 (en)	2010-10-20
DE60045138D1 (de)	2010-12-02
CY1106762T1 (el)	2012-05-23
IL214413A (en)	2014-04-30
ATE445018T1 (de)	2009-10-15
ES2231103T3 (es)	2005-05-16
EP1550722B1 (en)	2007-06-13
DE60035229T2 (de)	2008-02-21
DE60014489T2 (de)	2005-11-24
ES2354578T3 (es)	2011-03-16
ATE519855T1 (de)	2011-08-15
ES2372824T3 (es)	2012-01-26
AU4954700A (en)	2000-12-05
ATE364707T1 (de)	2007-07-15
KR100741247B1 (ko)	2007-07-19
PT1054064E (pt)	2005-02-28
JP4843145B2 (ja)	2011-12-21
EP1681353A1 (en)	2006-07-19
DK1816205T3 (da)	2011-11-21
PT1818408E (pt)	2011-11-15
ATE485382T1 (de)	2010-11-15
EP1054064A1 (en)	2000-11-22
EP1816205A1 (en)	2007-08-08
DE60014489D1 (de)	2004-11-11
KR20020028879A (ko)	2002-04-17
CY1112189T1 (el)	2015-12-09
CY1112008T1 (el)	2015-11-04
CA2372655A1 (en)	2000-11-23
DK1054064T4 (da)	2010-05-03
CY1111494T1 (el)	2015-08-05
IL214413A0 (en)	2011-09-27
DE60043126D1 (de)	2009-11-19
ATE278792T1 (de)	2004-10-15
DK1818408T3 (da)	2011-10-17
PT1816204E (pt)	2011-01-24
ATE519854T1 (de)	2011-08-15
JP5335037B2 (ja)	2013-11-06
DE60014489T3 (de)	2010-08-12
DK1681353T3 (da)	2010-01-04
EP1816205B1 (en)	2011-08-10
ES2289426T3 (es)	2008-02-01
IL146479A0 (en)	2002-07-25
AU777041B2 (en)	2004-09-30
PT1816205E (pt)	2011-11-15
WO2000070071A1 (en)	2000-11-23
ES2231103T5 (es)	2010-04-15
NZ515582A (en)	2003-11-28
JP2002543846A (ja)	2002-12-24
DK1550722T3 (da)	2007-10-08
EP1054064B1 (en)	2004-10-06
EP1818408B1 (en)	2011-08-10
EP1054064B2 (en)	2009-12-16
EP1816204A1 (en)	2007-08-08
CA2372655C (en)	2011-11-15
EP1818408A1 (en)	2007-08-15
DE60035229D1 (de)	2007-07-26
EP1550722A1 (en)	2005-07-06
JP2011224014A (ja)	2011-11-10
PT1550722E (pt)	2007-09-25
IL146479A (en)	2011-12-29
DK1054064T3 (da)	2005-01-10
ES2372823T3 (es)	2012-01-26

Publication	Publication Date	Title
DK1816204T3 (da)	2011-01-24	Rekombinant adenovirus af Ad26-serotypen
Douglas et al.	2001	Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors
JP2002537816A5 (da)	2011-02-24
NZ336829A (en)	2001-03-30	Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype
FI971613A7 (fi)	1997-04-16	Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
NO20020276L (no)	2002-03-15	In vitro seleksjon og valgfri identifikasjon av polypeptider ved bruk av fast-fase-b¶rere
EP0648271A4 (en)	1994-11-25	ADENOVIRUS INDUCED TRANSFER OF GENES TO THE GASTROINTESTINAL PATHWAY.
DE60000008D1 (de)	2001-09-20	Belüftete Scheibe für Scheibenbremse
FI20002392L (fi)	2002-05-01	Menetelmä ja valmiste asetaldehydin sitomiseksi, mahalaukussa ja paksusuolessa
Kangasniemi et al.	2006	Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer
WO2004099422A3 (en)	2005-01-13	Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
Nettelbeck	2003	Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis
JP2008508899A5 (da)	2008-09-18
WO2006086357A3 (en)	2007-02-01	Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
Wakayama et al.	2007	E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR–Deficient Biliary Cancers
WO2004035616A3 (de)	2004-05-27	Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
CN201482137U (zh)	2010-05-26	折叠式棋盘
AU2001284511A1 (en)	2003-06-19	Impartment of virus-resistance with the use of plant protein binding to plant virus transport protein
WO2002086709A3 (en)	2002-12-19	Method and system for plug-in mapper
WO2001081607A3 (en)	2002-06-13	Adenovirus vectors with knobless fibers, and their uses
Cook et al.	2000	A Winter’s Tale
Strauss et al.	1994	Orchestral works
Hasegawa et al.	2000	Ultrastructural evaluation of apoptosis induced by Helicobacter pylori infection in gastric mucosa: The novel remarks on lamina propria mucosae
Asgharian et al.	1990	A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q]
Doko et al.	2001	VIDEO ASSISTED ESOPHAGEAL RESECTION DURING OPEN TRANSHIATAL ESOPHAGECTOMY